Search results “Clinical trials for lung cancer treatments”
New Cancer Treatment Is Incredibly Effective
Researchers from Stanford University looked into a possible cancer vaccine and through their clinical trials found out it is incredibly effective. Ana Kasparian, Grace Baldridge, and Mark Thompson, hosts of The Young Turks, discuss. Tell us what you think in the comment section below. http://www.tytnetwork.com/join Read more here: https://www.livescience.com/62161-cancer-vaccine-trial.html "A promising new cancer "vaccine" that cured up to 97 percent of tumors in mice will soon be tested in humans for the first time — but experts say that we're still a long way off from this type of drug being prescribed to cancer patients. Researchers from Stanford University will test the therapy in about 35 people with lymphoma by the end of the year, according to SFGate, a local news outlet in San Francisco. The treatment stimulates the body's immune system to attack cancer cells. In studies in mice with various cancers — including lymphoma, breast cancer and colon cancer — the treatment eliminated cancer tumors in 87 out of 90 mice, even when the tumors had spread to other parts of the body, the researchers said." Hosts: Ana Kasparian, Grace Baldridge, and Mark Thompson Cast: Ana Kasparian, Grace Baldridge, and Mark Thompson *** The Largest Online News Show in the World. Hosted by Cenk Uygur and Ana Kasparian. LIVE STREAMING weekdays 6-8pm ET. https://goo.gl/tJpj1m Subscribe to The Young Turks on YouTube: https://goo.gl/a3JY9i Like The Young Turks on Facebook: https://goo.gl/txrhrh Follow The Young Turks on Twitter: https://goo.gl/w6ahdV Buy TYT Merch: https://goo.gl/KVysaM Download audio and video of the full two hour show on-demand + the members-only post game show by becoming a member at https://goo.gl/v8E64M. Your membership supports the day to day operations and is vital for our continued success and growth. Young Turk (n), 1. Young progressive or insurgent member of an institution, movement, or political party. 2. A young person who rebels against authority or societal expectations.(American Heritage Dictionary)
Views: 135022 The Young Turks
Clinical Trial Immunotherapy for Lung Cancer Treatment
New advances in treatment are helping more people, like Natalie Kelly, survive lung cancer. After chemotherapy did not work, she turned to a clinical trial for immunotherapy. Learn more from Dr. Suman Rao as she discusses immunotherapy for lung cancer treatment. To learn more about lung cancer treatment visit http://bit.ly/2iXiO2z.
Views: 151 MedStar Health
Clinical trial was the right choice for lung cancer survivor
When Georgia Dominick was diagnosed with stage IV metastatic lung cancer in Aug. 2014, an Alabama oncologist told her she only had a year left to live. But Georgia didn’t accept that prognosis and came to MD Anderson instead. Here, she took part in a clinical trial involving a new immunotherapy drug for people with her exact type of cancer. She is now two years post-diagnosis, and is considered in remission. “If I had the choice of going anywhere else in the world for free, I would stay right here,” she says. MD Anderson offers many clinical trials for all different cancers. To learn more about clinical trials and search for clinical trials, visit https://www.mdanderson.org/patients-family/diagnosis-treatment/clinical-trials.html
The Latest in Lung Cancer Treatment
From radiation to immunotherapy to clinical trials, learn more about the most current lung cancer treatments from the experts at Levine Cancer Institute.
Overcoming Terminal Lung Cancer with Clinical Trial - Lehigh Valley Health Network
When war veteran Jonathan Gyuran experienced chest pains at work, he thought he was having a heart attack. Within 24 hours, tests conducted at Lehigh Valley Health Network revealed the true cause: cancer that had spread to both lungs. Lehigh Valley Health Network medical oncologist Brian Patson, MD, suggested a clinical trial that was ultimately able to help Jonathan beat the odds and put his cancer into remission. Lehigh Valley Health Network Cancer Institute is proud to be part of the Memorial Sloan Kettering Cancer Alliance, an initiative to improve the quality of care and outcomes for patients with cancer in community health settings. Learn more about our clinical trials and partnership with the Memorial Sloan Kettering Cancer Alliance at LVHN.org/msk.
Living Healthy:  Clinical Trials for Lung cancer
Living Healthy: Clinical Trials for Lung cancer
Views: 50 KHON2 News
Navigating Clinical Trials and Treatments for Lung Cancer
Lung Cancer Alliance clinical research coordinator Andrew Ciupek speaks about recent progress in lung cancer advocacy and enrolling in clinical trials. Learn more about NYU Langone’s Perlmutter Cancer Center: http://nyulangone.org/locations/perlmutter-cancer-center
Views: 24 NYU Langone Health
Immunotherapy: A Cancer Breakthrough at Penn Medicine (:60)
What if your immune system could fight cancer? Now it can with a cancer treatment created by Penn Medicine called CAR T cell therapy. CAR T is a form of immunotherapy that reprograms your body's own immune cells to seek and destroy every last cancer cell. CAR T CELL THERAPY FOR LEUKEMIA In a landmark decision, the FDA approved Penn's CAR T cell therapy for people up to the age of 25 years old with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). It is the first-ever gene therapy in the world available on the market and begins a new era of cancer treatment. Learn more about immunotherapy at Penn: http://bit.ly/2gwa96x If you are interested in or have questions about CAR T therapy, please call 215-316-5127 or fill out our contact form: http://bit.ly/2ydyYMm CAR T CELL THERAPY FOR OTHER CANCERS Our success in CAR T cell therapy does not stop with leukemia. We are also testing a similar therapy to treat non-Hodgkin’s lymphoma and have a request for FDA approval underway. There are a number of CAR T clinical trials available at Penn Medicine for all different forms of cancer. Many of our clinical trials aren't available anywhere else. View available clinical trials: http://bit.ly/2ycocpJ Learn about clinical trials by watching the video "What Is a Clinical Trial?": https://youtu.be/nz94pcvHJ3k Request an appointment: http://bit.ly/2ydyYMm
Views: 6613 Penn Medicine
Lung cancer survivor: Advice for cancer patients considering a clinical trial
After a CT scan revealed a 5 cm mass on his lung, lung cancer patient Tom Barber underwent a video-assisted thoracotomy at The University of Texas MD Anderson Cancer Center in August 2009. He subsequently considered chemotherapy and a clinical trial for follow-up lung cancer treatment. Ultimately, Barber chose to participate in a clinical trial. Although he experienced many side effects as a result of the clinical trial, he encourages other cancer patients to participate in a clinical trial, if there's one that's appropriate for their particular cancer diagnosis. Today, Barber is lung cancer-free. Read Barber's story: http://www.cancermoonshots.org/stories-hope/tom-barber Learn about MD Anderson's Lung Cancer Moon Shot: http://www.cancermoonshots.org/moon-shots/lung
New Options for Lung Cancer Therapies
Dr. Joel Neal, a Stanford Cancer Institute researcher and oncologist, discussed clinical research on lung cancer therapies with a focus on immunotherapy and other targeted approaches.
Views: 2645 Stanford Health Care
Lung Cancer Clinical Trials: Advances in Immunotherapy
NCI’s Dr. Shakun Malik, head of thoracic oncology therapeutics, and Janet Freeman-Daily, lung cancer patient activist and founding member of #LCSM, host a 30-minute Facebook Live event. The event streamed on November 17 at 8:00 pm ET on http://www.Facebook.com/cancer.gov. For more information on lung cancer, go to http://www.cancer.gov/lung
Lung Cancer: New Therapies and Clinical Trials | City of Hope's Karen Reckamp, M.D.
Karen Reckamp, M.D., co-director of the Lung Cancer and Thoracic Oncology Program, discusses her focus on clinical trials and new treatments for lung cancer. For more information on City of Hope's lung cancer program, please go to: http://www.cityofhope.org/lung-cancer ############################ City of Hope is a leading research and treatment center for cancer, diabetes and other life-threatening diseases. Designated as a comprehensive cancer center, the highest recognition bestowed by the National Cancer Institute, City of Hope is also a founding member of the National Comprehensive Cancer Network, with research and treatment protocols that advance care throughout the nation. City of Hope's main hospital is located in Duarte, Calif., just northeast of Los Angeles, with community clinics in southern California. It is ranked as one of "America's Best Hospitals" in cancer by U.S.News & World Report. Founded in 1913, City of Hope is a pioneer in the fields of bone marrow transplantation and genetics. For more information, visit www.cityofhope.org. ############################ CONNECT WITH CITY OF HOPE http://www.facebook.com/cityofhope http://www.twitter.com/cityofhope http://breakthroughs.cityofhope.org http://thehelix.cityofhope.org http://www.pinterest.com/cityofhopepins http://www.flickr.com/cityofhope http://www.causes.com/cityofhope and more at http://www.cityofhope.org/getsocial
Views: 1170 City of Hope
Tremelimumab and durvalumab therapy in lung cancer
Rosalyn Juergens, MD, PhD of McMaster University, Juravinski Cancer Centre, Canada gives an overview of her presentation of the data from the Canadian Clinical Trials Group Investigational New Drug Committee (IND), trial IND.226 (NCT02537418). This looked at quadruple therapy in lung cancer, which was chemotherapy plus two different forms of immunotherapy, CTLA-4 inhibitor (tremelimumab) and PD-L1 inhibitor (durvalumab). This was a Phase I, dose escalation study looking at safety and tolerability. Combinations of immuno-oncology drugs have been a challenge in the past, so seeing whether patients can sustain the treatment before moving onto quadruple therapy was important. It was found that patients could sustain it, with incremental increases in the manageable side effects to patients. There was an increase in fatigue, a slight increase in diarrhea, as well as pneumonitis, hypothyroidism and hyperthyroidism. Efficacy in terms of response rate was double what would be expected with just chemotherapy alone. It is slightly higher than what has been seen with chemotherapy plus a PD-1 or PD-L1 inhibitor. However, they are awaiting further results and hoping for increased durability. Recorded at the 2016 World Conference of Lung Cancer (WCLC) of the International Association for the Study of Lung Cancer (IASLC) in Vienna, Austria.
Views: 478 VJOncology
Non-Small Cell Lung Cancer Clinical Trial
Nasser Hanna, MD, discusses a phase II trial of concurrent chemoradiation with consolidation Pembrolizumab for the treatment of inoperable or unresectable stage III non-small cell lung cancer (NSCLC). Hoosier Cancer Research Network: LUN14-179 http://www.hoosiercancer.org/clinical-trials
Lung Cancer Clinical Trial for NSCLC
A new and innovative lung cancer clinical trial is being conducted at UCLA. This trial tests the use of an aromatase inhibitor in conjunction with the standard lung cancer chemotherapy to find better treatments and hopefully cures for lung cancer. This trial is based upon the concept that estrogen serves as the basic fuel for lung cancer. The trial is for advanced non-small cell lung cancer (NSCLC).
Views: 297 Demand Cures
Lung cancer patient says clinical trial is a miracle
Hear one man's journey as he battles lung cancer with a new treatment he says saved his life.
Views: 19 Amy Leet
New Immunotherapy Drugs Offer Even More Treatment Options and Hope for Lung Cancer Patients
New clinical trials here at The James offer even more hope and options for lung cancer patients, thanks to new immunotherapy drugs recently approved for lung cancer treatments. These drugs work with the body’s own immune system, and they maintain lower toxicity, frequent tumor shrinkage and long-lasting responses for patients. And with new clinical trials researching their use in combination with other treatments, with surgery or, in some cases, even as the first treatment response for lung cancer, many patients are experiencing fewer side effects, shorter recovery times, and longer-lasting results.
How to Improve Lung Cancer Treatments | Cancer Research UK
Dr Corinne Faivre-Finn is leading a major international clinical trial called CONVERT, which hopes to find the best treatment for small cell lung cancer (SCLC). Learn more about the trial, which aims to discover the most effective chemotherapy and radiotherapy schedule for people with SCLC. To find out more, visit http://myprojects.cancerresearchuk.org/projects/lung-cancer
Views: 1566 Cancer Research UK
ValiSeek chief discusses upcoming clinical trials of lung cancer drug
Suzanne Dilly, the chief executive officer of ValiSeek, a division life sciences firm ValiRx (LON:VAL), explains the company’s deal with Clinical Accelerator to carry out the work on a Phase IIB study for lung cancer treatment VAL 401. The drug is being developed through a joint venture with Tangent Profiling to target patients with non-small-cell lung adenocarcinoma, the most common form of the disease.
Clinical Trial Helps Patient Battle Stage Four Lung Cancer
Jennifer Williams had never smoked or even lived with anyone who smoked but was diagnosed with stage four lung cancer three years ago. Florida Hospital Thoracic Cancer Medical Director Dr. Tarek Mekhail put Jennifer on a clinical trail for a new lung cancer treatment and her cancer reduced by half. Jennifer is now on the second generation of this medication and is getting back to her normal life- including roller skating with her kids!
Views: 718 Florida Hospital
Zee News - Kusum stage IV lung cancer patient message to support clinical trails in India
It is short interview/ story of Kusum, a patient of stage IV lung cancer metastatic to brain (multiple tumors), to support and raise awareness of clinical trials in India, as taken by Zee news, a Hindi National News Channel in India. 5 yrs back, though being a non-smoker, at the age of 29, Kusum was diagnosed with stage IV. In 2014, when her disease got resistant to all available applicable medicines in India (though they were available in western countries via approval or clinical trials). She almost lost her life to this dreadful disease due to unavailability of any medicine. To get any cancer medicine approved in India, it should go for clinical trials, whether it is already approved in other countries or not. In India, there are only 1.4% of global trails going on, which leads to almost no access of the latest medicines/ treatment options for Indian citizens. Fortunately, after 3 months of battle of survival, Kusum came across a new clinical trial in India and decided to participate. After experiencing how clinical trial saved Kusum’s life and struggle associated to get access to latest medicines and clinical trial, Kusum and her husband Vivek have started to work actively with Patients, NGOs, Industry organizations, Regulators at FDA/ Govt and Doctors on clinical trial awareness and raising support to change the current clinical trial situation in India. So that no Indian patient should die due to unavailability of medicine that is available somewhere in world.
Views: 13854 Vivek Tomar
This Cuban lung cancer drug is giving some U.S. patients hope
A promising lung cancer treatment from Cuba is getting attention from U.S. patients, some of whom are already traveling there to try the drug in hopes of stopping their cancer from growing. American doctors can't prescribe CIMAvax because the Food and Drug Administration won’t approve it until U.S. clinical trials can prove its effectiveness. Special correspondent Amy Guttman reports.
Views: 10328 PBS NewsHour
MGH Clinical Trial for Lung Cancer: Targeted Therapies to Halt Tumor Growth
Linnea Duff tells her story about participating in a clinical trial of a potential new targeted treatment drug that has provided powerful evidence that it can halt or reverse the growth of lung tumors characterized by a specific genetic abnormality. In their report in the October 28 New England Journal of Medicine, a multi-institutional research team reports that daily doses of the investigational drug crizotinib shrank the tumors of more than half of a group patients whose tumors were driven by alterations in the anaplastic lymphoma kinase (ALK) gene. In another one-third of study participants, crizotinib treatment suppressed tumor growth. Fore more information visit: http://www.massgeneral.org/cancer/news/faq.aspx Press Release: http://www.massgeneral.org/about/pressrelease.aspx?id=1292
Views: 1759 MassGeneralHospital
Dr. Daly on Clinical Trials With Radiation Therapy in Lung Cancer
Megan E. Daly, MD, assistant professor of radiation oncology, UC Davis Cancer Center, discusses upcoming clinical trials involving radiation therapy for the treatment of lung cancer.
Views: 116 OncLiveTV
Lung cancer clinical trial
This video is intended for non-US residents. A clinical trial is a research study involving people. Therapies to treat lung cancer today are the result of clinical trials from the past. For more information about clinical trials visit: www.nationallungcancerpartnership.org www.lungcancercoalition.org For more information on lung cancer and lung cancer treatments, visit: http://www.lifewithlungcancer.info
Views: 366 LifeWithLungCancer
Lung cancer - Part 18 - Clinical trials & new treatments
Clinical trials are a vital part of the search for new cancer treatments. It's important that people with cancer talk to their doctors about clinical trials and understand what's involved, so they can make informed decisions about participating.
Non-Small Cell Lung Cancer (NSCLC) Immunotherapy: Advancing Hope
SITC presents NSCLC Immunotherapy: Advancing Hope, the newest in a series of videos focusing on immunotherapy for NSCLC patients. This video provides an overview of the building blocks of the immune system and immunotherapy, while also highlighting some of the FDA approved immunotherapy treatments and potential side effects, and the importance of clinical trials. *This video was produced prior to the October 2016 FDA approvals of 1) TECENTRIQ® (atezolizumab, Genetech, Inc.) in patients whose disease progressed despite treatment with platinum-containing chemotherapy and 2) KEYTRUDA® (pembrolizumab; Merck & Co., Inc.) as first-line therapy in patients whose tumors express high levels of PD-L1 on an FDA-approved test, without certain genetic mutations (EGFR or ALK). As a leader in the field of cancer immunotherapy research and education, SITC will continue to update this video series as additional immunotherapy treatments become available. Access Companion Online Activity: https://www.cmeuniversity.com/course/disclaimer/113314
Cancer survivor Philip Prichard’s clinical trial success story
Physicians at MD Anderson Cancer Center proposed a clinical trial for Philip Prichard using immunotherapy – a unique and personal approach to treating cancer tumors. After 8 weeks his tumor shrunk in half. After 13 months 75% of the tumor was gone. Learn more at http://makingcancerhistory.com
Views: 1225030 MD Anderson Cancer Center
Lung Cancer Clinical Trial: Taxotere with or without Opdivo
Learn about a clinical trial that may help answer questions about the role of immunotherapy in combination with chemotherapy in treating patients with advanced non-small cell lung cancer whose disease worsened after initial response to immunotherapy. http://hoosiercancer.org/clinical-trials/trial/lun15-233/
Governor Cuomo Announces Groundbreaking Clinical Trial of Cuban-Developed Lung Cancer Treatment
October 26, 2016, Buffalo - Governor Cuomo announced that the Buffalo-based Roswell Park Cancer Institute will launch a groundbreaking clinical trial of CIMAvax-EGF – a Cuban-developed lung cancer treatment.
Views: 951 NYGovCuomo
Lung Cancer and a Clinical Trial | Abi's Story
Abi had stage 4 lung cancer. She turned to Penn's Abramson Cancer Center for treatment, and we connected her with a clinical trial for lung cancer. Eight years, and four grandkids later, Abi radiates hope. #CureIsWithin
Views: 2067 Penn Medicine
Surviving With Metastatic Lung Cancer Thanks to Research
November is Lung Cancer Awareness Month. Learn how cancer targeted therapy and clinical trials are helping Ginger live well with stage 4 lung cancer: http://the.aacr.org/kr3E
Immunotherapy Clinical Trials: Sue Scott’s Story of Survival
An inside look at a Center for Cancer Research trial with Dr. Christian Hinrichs and his patient, Sue Scott. Dr. Hinrichs conducts basic and clinical research to discover and develop novel T-cell therapies for the treatment of patients with cancer. This work includes a clinical trial of HPV-targeted tumor-infiltrating T cells for patients with HPV+ cancers, which has demonstrated that this treatment can mediate complete regression of cervical cancer in some patients. Dr. Hinrichs' laboratory also has discovered genes for T-cell receptors that target HPV, and his group is testing new gene therapy treatments based on these receptors for patients with advanced HPV+ tumors. The Center for Cancer Research (CCR) is a part of the National Cancer Institute. For more on CCR: https://ccr.cancer.gov/ To search for clinical trials: http://trials.cancer.gov
New Lung Cancer Study tests effectiveness of genomic therapy
Watch more and discuss: http://norwalk.itsrelevant.com/content/19695/whittingham-changing-lung-cancer-treatment A new drug through a clinical trial at Norwalk Hospital is changing the way doctors are treating lung cancer. "We've now been able to identity a couple of specific genetic changes that can be targeted with drugs. Right now it is standard of care to treat some patients who have a mutation in the gene called EGFR (epidermal growth factor receptor) with a drug called Tarceva or another drug calledafatinib,"said Dr. Richard Frank, medical oncologist and Director of Cancer Researcha at Norwalk Hospital. Lung cancer is the leading cause of cancer death in men and women.According to the American Cancer Society (ACS), each year more people die of lung cancer than of colon, breast, and prostate cancers combined. There are two major types of lung cancer, non-small cell and small cell. Diagnostic testing guides treatment by determining the type and stage of the cancer, as well as genetic mutations in the cancer cells. According to Dr. Richard Frank, the medicine targets a specific gene mutation in patients tumors. "This mutation is more common in people who did not smoke and developed lung cancer. There is a population especialy in young women, that is rising exponentially but we do not know why." With the new drugs, patients now have another treatment option other than traditional chemotherapy. "Now it's gene abnormality - pill. It is a targeted approach, said Dr. Frank. And Dr. Frank says the drugs are yielding promising results. "Not all the cells are killed but patients can enjoy remission of many months or many years in some cases. There has been a phase I trial already done and most of the patients responded so we know this pill is very active. We are now in the expansion trial meaning more people will recieve the drug, and probably as a result of this, the drug will recieve approval [from the FDA]. For more information about this clinical trial or about the cancer research program at Norwalk Hospital, please contact Jennifer M. Long, ANP-BC, nurse practitioner and clinical coordinator, Whittingham Cancer Center, 203-852-2996 or email Jennifer.long@norwalkhealth.org Produced By: Kwegyirba Croffie
Views: 110 It's Relevant TV
Cancer clinical trials - Placebos explained
This video is intended for non-US residents. Talk with your doctor about whether the clinical trial you may be considering involves a placebo arm and what that means. The placebo can be the standard of care or the standard of care plus the new treatment. For more information on lung cancer and lung cancer treatments, visit: http://www.lifewithlungcancer.info
Views: 492 LifeWithLungCancer
Immunotherapy for Lung Cancer: Currently Enrolling Clinical Trials of Combination Therapies
http://cancerGRACE.org/ Immunotherapy Forum Video #25: In Part 2 of 2 videos, Dr. Matthew Hellmann discusses currently enrolling clinical trials for lung cancer patients that study combination therapies (meaning an immunotherapy drug plus another drug is given).
For many lung cancer patients, Keytruda is a better initial treatment than chemotherapy, study finds
For many lung cancer patients, Keytruda is a better initial treatment than chemotherapy, study finds lung cancer, immunotherapy, chemotherapy, cancer treatment, clinical trials, medical research, ASCO, American Society of Clinical Oncology https://www.youtube.com/channel/UCd4_4MPV20qVj80Rm_cQHOw?sub_confirmation=1 In findings that may allow many lung cancer patients to avoid chemotherapy, a large clinical trial has shown that the immunotherapy drug Keytruda is a more effective initial treatment for two-thirds of patients with the most common type of lung cancer. Compared with advanced small-cell lung cancer patients who got chemotherapy, those treated first with Keytruda had a median survival time that was four to eight months longer. Advertisement The difference was greatest among patients whose cancers harbored high levels of the genetic mutations Keytruda uses to target malignancy. But even patients whose cancers had very low levels of these mutations outlived patients who got chemotherapy by a median of four months. In addition, treating lung cancer patients with Keytruda improved quality of life. Among those who got the immunotherapy drug, only 18% experienced severe side effects, compared with 41% on chemotherapy. The findings, presented this week at the annual meeting of the American Society of Clinical Oncology, will probably expand Keytruda’s use as a first-line treatment for advanced small-cell lung cancer, the most common form of the disease. At the same time, it’s sure to raise dilemmas for physicians and insurers struggling to identify when and in which advanced lung cancer patients the use of a very costly new medication makes sense. A year’s therapy with Keytruda can cost as much as $150,000. The cost of the chemotherapy cocktails to which it was compared in the new study is a few thousand dollars. In 2016, the Food and Drug Administration approved the marketing of Keytruda (also known as pembrolizumab) for use in lung cancer patients whose cancers had been genetically tested and were found to have levels of PD-L1 — a mutation that Keytruda targets — of 50% or higher. About one-third of patients with advanced non-small cell lung cancer meet this criterion. The new clinical trial, called Keynote-042, tested Keytruda’s effectiveness in newly diagnosed patients whose PD-L1 levels were as low as 1% — a population that represents two-thirds of those with small cell lung cancer. Researchers randomly assigned 1,274 people with advanced disease to receive one of two kinds of chemotherapy — either paclitaxel (marketed as Taxol) plus carboplatin or pemetrexed (marketed as Alimta) plus carboplatin — or Keytruda. Then, researchers followed their cases for a median of 12.8 months. Among patients whose PD-L1 levels were from 1% to 19%, those who got Keytruda lived for a median of 16.7 months after diagnoses while those who got chemotherapy lived a median of 12.8 months. Among patients with PD-L1 levels from 20% to 49%, those who got Keytruda lived a median of 17.7 months compared with 13 months for patients on chemotherapy. Patients whose PD-L1 levels were above 50% — those for whom Keytruda already has the FDA’s blessing — survived a median of 20 months with Keytruda, compared with 12.2 months for chemotherapy. The study has not yet
Views: 21 News Dongo
Lung cancer trial for patients with prior response to immunotherapy
Learn about a clinical trial that may help answer questions about the role of immunotherapy in combination with chemotherapy in treating lung cancer patients whose disease worsened after initial response to immunotherapy. The single-arm phase II trial, known as BTCRC-LUN15-029, involves Keytruda in combination with next-line chemotherapy in non-small cell lung cancer. http://www.bigtencrc.org/clinical-research/current-trials/btcrc-lun15-029/
Dr. Bassel El-Rayes explains how cancer clinical trials can be possible cancer treatment options
Dr. Bassel El-Rayes explains how cancer clinical trials can be possible cancer treatment options. Part of an interview about the cancer clinical trial process.
Views: 1103 CancerQuest
Patient to Patient: What You Need to Know About Cancer Immunotherapy
How does a cancer diagnosis interrupt your life? Why choose immunotherapy? Two patients offer two very different perspectives on life with cancer, choosing a clinical trial, and figuring out what's next in life. In this webinar designed for patients and caregivers, T.J. Sharpe and Donna Fernandez share their experiences with cancer immunotherapy as well as share advice for patients currently seeking or receiving immunotherapy treatment. T.J. Sharpe, was diagnosed with metastatic melanoma in 2012, just weeks after the birth of his second child. Not satisfied with the standard of care treatments offered to him, he and his family began exploring immunotherapy. Two clinical trials later, he is living a full life, now on maintenance Keytruda, devoting the bulk of his time to his family and to melanoma advocacy. T.J. writes a blog for philly.com called Patient 1. (The name of his blog was inspired by the first clinical trial he enrolled in at Moffit Cancer Center, in which he was the first patient ever to receive Yervoy and TIL (tumor-infiltrating lymphocytes, a type of adoptive cell transfer).) Donna Fernandez was first diagnosed with stage 4 lung cancer in 2012, when she went to the doctor believing she had a thyroid problem. At the time, Donna was working full time and doing dog agility several nights a week and every weekend. Her tumors did not respond to chemotherapy, and when faced with beginning a second chemotherapy regimen, Donna instead enrolled in an immunotherapy trial of nivolumab (Opdivo). Donna responded immediately. Her scans show that the tumors have remained stable. Donna continues training with her two dogs, Cotton and Barney. She says, “Opdivo has let me live my life exactly how I want to. People talk about a “new normal” after cancer, but I don’t have a new normal. I’m still living my old normal.” The "Cancer Immunotherapy and You" webinar series is produced by the Cancer Research Institute and is made possible with generous support from Bristol-Myers Squibb, with additional support from Regeneron, Sanofi Genzyme, and Adaptimmune. Browse our Cancer Immunotherapy and You Webinar Series playlist on YouTube or visit the Webinars page on our website to see other webinars in this series. http://www.cancerresearch.org/webinars
Clinical Trials - Lung Cancer Foundation of America (LCFA)
Leading lung cancer investigators Dr. Jessica Donington, Dr. David Johnson, Dr. Robert Figlin, Dr. David Carbone, Dr. Heather Wakalee and Dr. William Pao answer your questions, calm your fears and give hope regarding clinical trials and lung cancer treatments. Saving lives through funding lung cancer research is the purpose of Lung Cancer Foundation of America; a lung cancer organization founded by lung cancer advocates Kim Norris, Lori Monroe and David Sturges. LCFA will accomplish this goal by raising funds from the private sector and channeling those funds to lung cancer investigators, enabling clinicians and s to find effective ways to predict, detect and treat lung cancer. Lung Cancer Foundation of America strives to be a community resource for both the lung cancer patient and the lung cancer research communities. Learn more about Lung Cancer Foundation of America and donate to fund lung cancer research at www.lcfamerica.org.
Current Status of Immunotherapy in Lung Cancer
Panelists discuss ongoing clinical trials and research investigating immune checkpoint inhibitors as treatment for patients with non-small cell lung cancer. For more from this discussion, visit http://www.onclive.com/peer-exchange/nsclc-outcomes
Views: 668 OncLiveTV
THC (marijuana) Helps Cure Cancer Says Harvard Study
Daily News @ http://RevolutionNews.US ~ Researchers at Harvard tested the chemical THC in both lab and mouse studies. They say this is the first set of experiments to show that the compound, THC actually activates naturally produced receptors to fight off lung cancer. The researchers suggest that THC or other designer agents that activate these receptors might be used in a targeted fashion to treat lung cancer. Although a medical substitute of THC, known as Marinol, has been used as an appetite stimulant for cancer patients and other similar treatments, few studies have shown that THC might have anti-tumor activity. *HERE IS THE INTERESTING PART* The only clinical trial testing THC as a treatment against cancer growth was a recently completed British pilot study. For three weeks, researchers injected standard doses of THC into mice that had been implanted with human lung cancer cells, and found that tumors were reduced in size and weight by about 50 percent in treated animals compared to a control group. There was also about a 60 percent reduction in cancer lesions on the lungs in these mice as well as a significant reduction in protein markers associated with cancer progression. http://PhoenixTears.ca -- Cannabis stops cancer (Harvard) Cannabis stops breast cancer (UCSF) Cannabis grows brain cells in mice (Princeton) Cannabis is a cousin of the HEMP plant... HEMP Can't get you high yet it's illegal... HEMP is Illegal because it's the most useful plant in the world... it's the best fuel, paper, fiber, food, shelter... and corporations can't patent a plant! "HEMP can't get you high unless you smoke a joint the size of a telephone pole!" Dr. Ron Paul -- Time For A New American Revolution? ♥☠✿☮❀☠✿☮❀☠✿♥❀☠✿☮❀☠ http://RevolutionNews.us ☠✿☮❀☠✿☮❀☠✿♥
Views: 197802 marijuana420medicine
Carboplatin and Etoposide Lung Cancer Clinical Trial
UW Carbone Cancer Center physician Ticiana Leal, MD, explains this study of carboplatin and etoposide, chemotherapy medications used to treat small cell cancers, including small cell lung cancer.
Views: 506 UW Health
Advanced Lung Cancer Treatment at City of Hope | Dr. Karen Reckamp
Karen Reckamp, M.D., M.S., co-director of the Lung Cancer and Thoracic Oncology Program, discusses lung cancer treatment at City of Hope. ABOUT THE LUNG CANCER AND THORACIC ONCOLOGY PROGRAM The most advanced diagnostic and radiation technologies available, access to our clinical trials program and the coordinated care of specialists combine to provide the best possible outcomes for lung cancer patients. For more information about the lung cancer/thoracic oncology treatment program, please go to: http://www.cityofhope.org/lung or call (800) 826-HOPE.
Views: 4025 City of Hope
Ben Haithcock, MD, Talks about Lung Cancer Treatment and Research
Interview Recorded: November 2009 Dr. Haithcock discusses symptoms of lung cancer, surgical and chemo-therapeutic clinical trials, and things people can do to decrease their chances of lung cancer. He also talks about the stigma associated with lung cancer.
Views: 583 UNC Lineberger
Immunotherapy Drug Shines In Lung Cancer Study
A new study finds that immunotherapy could be the new standard of care for lung cancer patients who are often diagnosed after their disease has spread. Researchers have found the drug Keytruda, when given along with standard chemotherapy, cut the risk of dying from the disease in half compared with chemo alone. Patients in the study had advanced non-small cell lung cancer, the most common type. The findings could prompt doctors to use immunotherapy as a first line of treatment for lung cancer, despite a hefty price tag of $13,000 per month.
Dr. Keith Flaherty: Genetics of Cancer, Targeted Therapies, and Clinical Trials
Dr. Keith T. Flaherty was the keynote speaker at a 2015 NCCS Cancer Policy Roundtable where he addressed the topic of the genetics of cancer. After speaking at the event, he joined us to discuss personalization of cancer treatment and the need for understanding the biologic basis of an individual's cancer, as well as the issue of defining cancers based on their site of origin (e.g. lung cancer, breast cancer, etc.) as it relates to clinical trials. Dr. Flaherty is director of the Henri and Belinda Termeer Center for Targeted Therapies at the Mass General Cancer Center and Associate Professor of Medicine at Harvard Medical School. Dr. Flaherty’s research and clinical focus is therapies for melanoma, with a particular expertise in targeted therapies.
Views: 352 CancerSurvivorship
10  - Clinical Trials in Cancer Treatment - Interview with Dr. Bruce Johnson
For additional information visit http://www.cancerquest.org/bruce-johnson-interview. Dr. BruceJohnson, Professor in the Department of Medicine at Harvard Medical School, is a lung clinician/researcher who is interested in developing and testing new targeted therapies to treat lung cancer. He also examines the differences between patients who respond to a particular treatment and those that do not fare as well. In this interview he discusses his research motivations. To learn more about cancer and watch additional interviews, please visit the CancerQuest website at http://www.cancerquest.org.
Views: 34 CancerQuest
Oncolytic Viruses to Cure Cancer? Health care, oncolytic virus research, future cancer therapy
More: http://www.virttu.com. How oncolytic viruses work to kill cancer cells in melanoma, head and neck, prostate cancer and glioblastoma brain timours. Replication of oncolytic viruses inside tumours. Pre-clinical trials. Phase I, Phase II and Phase III clinical trials on oncolytics. Use of oncolytic viruses to treat advanced malignant melanoma and mestatases -- Amgen research using an oncolytic virus developed from HSV (Herpes Simplex Virus). Oncolytic virus conference 2013. Problems with traditional chemotherapy -- side effects. Why Amgen bought an oncolytic viruse for $500m in cash and $500m to be paid if oncolytic trials are fully successful. Investor interest in oncolytic viruses. Oncolytic virus fund. Lessons from the history of research and development in monoclonal antibodies in cancer treatment. Why targeted cancer therapy -- a so-called "magic bullet" is so needed. How oncolytic viruses have been modified so that they cannot replicate in normal cells, but are still able to divide in a wide variety of human cancer cells. History of oncolytic viruses. Arming oncolytic viruses. Using viruses like Seprehvir (HSV-1716), adapted to carry an additional payload: extra genes which teach infected cancer cells to take up a compound containing radioactive iodine from the blood, delivering a micro-dose of radiation inside individual cancer calls. Or adding a gene which teaches cancer cells how to split a harmless pro-drug into two, inside the cell, releasing a very effective chemotherapy (alkylating agent). Targetting oncolytic viruses -- by adapting the feet of a virus to that they latch onto receptors on the surface of specific human cancer cells such as prostate (prostate antigens / PSA). Oncolytic virotherapy: Results of early Phase III Rheolysin clinical trials -- combined oncolytic virus and cancer chemotherapy. Side effects and safety profile of oncolytic viruses in clinical studies. Oncolytic virus Seprehvir has passed an FDA safety review with approval for systemic administration of oncolytic viruses to children with advanced cancer. How genes work in viruses, and how genetic engineering allows us to cut and paste genes from one species into another. Dr Video made by Patrick Dixon author of The Genetic Revolution, Chairman of Global Change Ltd, an advisor to many large pharma companies and Chairman of Virttu Biologics Ltd which owns the oncolytic virus Seprehvir (HSV-1716) and many other variants. Seprehvir has been shown to be highly effective against a wide range of cancers in pre-clinical studies. Seprehvir has been used in clinical trials with strong evidence of impact and almost negligible side effects - trials in glioblastoma (brain cancer), squamous cell carcinoma of head and neck and melanoma. Seprehvir is now being used in clinical trials for mesothelioma (lung cancer caused by asbestos), with others planned for hepatocellular carcinoma (live cancer) and ovarian cancer. OncoVEX GM-CSF developed by BioVex in phase III for advanced melanoma, could become first approved oncolytic virus in the western world. OncoVEX GM-CSF is also in a phase 3 trial for head and neck cancer. Reolysin (owned by Oncolytics Biotech) is in phase 3 clinical trials for head and neck cancer with early results in colorectal cancer. JX-594 is owned by Jennerex and in clinical trials for hepatocellular carcinoma. JX-594 is a thymidine kinase-deleted Vaccinia virus plus GM-CSF. NTX-010 is in clinical trials for small cell lung cancer and neuroblastoma. CGTG-102 (Ad5/3-D24-GMCSF) is owned by Oncos Therapeutics. GL-ONC1 is owned by Genelux in Phase I clinicla trials. Cavatak is being developed to treat malignant melanoma. Oncorine was approved a few years ago in China for treatment of head and neck cancer - built from H101 virus.